Literature DB >> 24231239

The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis.

George Rodrigues1, Himu Lukka, Padraig Warde, Michael Brundage, Luis Souhami, Juanita Crook, Fabio Cury, Charles Catton, Gary Mok, Andre-Guy Martin, Eric Vigneault, Jim Morris, Andrew Warner, Sandra Gonzalez Maldonado, Tom Pickles.   

Abstract

BACKGROUND: The Genitourinary Radiation Oncologists of Canada (GUROC) published a three-group risk stratification (RS) system to assist prostate cancer decision-making in 2001. The objective of this project is to use the ProCaRS database to statistically model the predictive accuracy and clinical utility of a proposed new multi-group RS schema.
METHODS: The RS analyses utilized the ProCaRS database that consists of 7974 patients from four Canadian institutions. Recursive partitioning analysis (RPA) was utilized to explore the sub-stratification of groups defined by the existing three-group GUROC scheme. 10-fold cross-validated C-indices and the Net Reclassification Index were both used to assess multivariable models and compare the predictive accuracy of existing and proposed RS systems, respectively.
RESULTS: The recursive partitioning analysis has suggested that the existing GUROC classification system could be altered to accommodate as many as six separate and statistical unique groups based on differences in BFFS (C-index 0.67 and AUC 0.70). GUROC low-risk patients would be divided into new favorable-low and low-risk groups based on PSA ⩽6 and PSA >6. GUROC intermediate-risk patients can be subclassified into low-intermediate and high-intermediate groups. GUROC high-intermediate-risk is defined as existing GUROC intermediate-risk with PSA >=10 AND either T2b/c disease or T1T2a disease with Gleason 7. GUROC high-risk patients would be subclassified into an additional extreme-risk group (GUROC high-risk AND (positive cores ⩾87.5% OR PSA >30).
CONCLUSIONS: Proposed RS subcategories have been identified by a RPA of the ProCaRS database.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Database; Prognosis; Prostatic neoplasms; Radiotherapy; Statistical model

Mesh:

Year:  2013        PMID: 24231239     DOI: 10.1016/j.radonc.2013.07.020

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  15 in total

1.  Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.

Authors:  Thomas M Pisansky; Daniel Hunt; Leonard G Gomella; Mahul B Amin; Alexander G Balogh; Daniel M Chinn; Michael J Seider; Marie Duclos; Seth A Rosenthal; Glenn S Bauman; Elizabeth M Gore; Marvin Z Rotman; Himanshu R Lukka; William U Shipley; James J Dignam; Howard M Sandler
Journal:  J Clin Oncol       Date:  2014-12-22       Impact factor: 44.544

2.  Metastatic progression following multimodal therapy for unfavorable-risk prostate cancer.

Authors:  David Guy; Rachel Glicksman; Roger Buckley; Patrick Cheung; Hans Chung; Stanley Flax; David Hajek; Andrew Loblaw; Gerard Morton; Jeffery Noakes; Les Spevack; Joseph L K Chin; George Rodrigues
Journal:  Can Urol Assoc J       Date:  2022-04       Impact factor: 2.052

3.  External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer.

Authors:  David Tiberi; George Rodrigues; Tom Pickles; Jim Morris; Juanita Crook; Andre-Guy Martin; Fabio Cury; Charles Catton; Himu Lukka; Andrew Warner; Daniel Taussky
Journal:  Can Urol Assoc J       Date:  2017 Mar-Apr       Impact factor: 1.862

4.  Active treatment in low-risk prostate cancer: a population-based study.

Authors:  S Roy; M E Hyndman; B Danielson; A Fairey; R Lee-Ying; W Y Cheung; A R Afzal; Y Xu; T Abedin; H C Quon
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

5.  Does adding local salvage ablation therapy provide survival advantage for patients with locally recurrent prostate cancer following radiotherapy? Whole gland salvage ablation post-radiation failure in prostate cancer.

Authors:  Shiva Madhwan Nair; Andrew Warner; Arnon Lavi; George Rodrigues; Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2021-04       Impact factor: 1.862

6.  Diagnosis, referral, and primary treatment decisions in newly diagnosed prostate cancer patients in a multidisciplinary diagnostic assessment program.

Authors:  David Guy; Gabriella Ghanem; Andrew Loblaw; Roger Buckley; Beverly Persaud; Patrick Cheung; Hans Chung; Cyril Danjoux; Gerard Morton; Jeff Noakes; Les Spevack; David Hajek; Stanley Flax
Journal:  Can Urol Assoc J       Date:  2016 Mar-Apr       Impact factor: 1.862

7.  Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer.

Authors:  Andrew Warner; Tom Pickles; Juanita Crook; Andre-Guy Martin; Luis Souhami; Charles Catton; Himu Lukka; George Rodrigues
Journal:  Cureus       Date:  2015-06-11

8.  Definitive 3D-CRT for clinically localized prostate cancer: modifications of the clinical target volume following a prostate MRI and the clinical benefits.

Authors:  Shinsaku Yamaguchi; Takayuki Ohguri; Masami Fujii; Katsuya Yahara; Yoshiko Hayashida; Naohiro Fujimoto; Yukunori Korogi
Journal:  Springerplus       Date:  2015-07-15

9.  Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.

Authors:  Vincent J Gnanapragasam; Artitaya Lophatananon; Karen A Wright; Kenneth R Muir; Anna Gavin; David C Greenberg
Journal:  PLoS Med       Date:  2016-08-02       Impact factor: 11.069

10.  Modeling-Based Decision Support System for Radical Prostatectomy Versus External Beam Radiotherapy for Prostate Cancer Incorporating an In Silico Clinical Trial and a Cost-Utility Study.

Authors:  Yvonka van Wijk; Bram Ramaekers; Ben G L Vanneste; Iva Halilaj; Cary Oberije; Avishek Chatterjee; Tom Marcelissen; Arthur Jochems; Henry C Woodruff; Philippe Lambin
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.